The Efficacy of Etanercept As Anti-Breast Cancer Treatment Is

Total Page:16

File Type:pdf, Size:1020Kb

The Efficacy of Etanercept As Anti-Breast Cancer Treatment Is Shirmohammadi et al. BMC Cancer (2020) 20:836 https://doi.org/10.1186/s12885-020-07228-y RESEARCH ARTICLE Open Access The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages Elnaz Shirmohammadi1, Seyed-Esmaeil Sadat Ebrahimi1, Amir Farshchi2 and Mona Salimi3* Abstract Background: Interaction between microenvironment and breast cancer cells often is not considered at the early stages of drug development leading to failure of many drugs at later clinical stages. Etanercept is a TNF-alpha inhibitor that has been investigated for potential antitumor effect in breast cancer with conflicting results. Methods: Secretome data on MDA-MB-231 cancer cell-line were from public repositories and subjected to gene enrichment analyses. Since MDA-MB-231 cells secrete high levels of Granulocyte-Monocyte Colony Stimulating Factor, which activates macrophages to promote tumor growth, the effect of macrophage co-culturing on anticancer efficacy of Etanercept in breast cancer was evaluated using the Boolean network modeling and in vitro experiments including invasion, cell cycle, Annexin PI, and tetrazolium based viability assays and NFKB activity. Results: The secretome profile of MDA-MB-231 cells was similar to the expression of genes following treatment of breast cancer cells with TNF-α. Accordingly, inhibition of TNF-α by Etanercept decreased MDA-MB-231 cell survival, induced apoptosis and cell cycle arrest in vitro and inhibited NFKB activation. The inhibitory effect of Etanercept on cell viability, cell cycle progression, invasion and induction of apoptosis decreased following co-culturing of the cancer cells with macrophages. The Boolean network modeling of the changes in the dynamics of intracellular signaling pathways revealed NFKB activation by secretome of macrophages, leading to a decreased efficacy of Etanercept, suggesting NFKB inhibition as an alternative approach to inhibit cancer cell growth in the presence of macrophage crosstalk. Conclusion: This study indicates that the effect of Etanercept may be influenced by residing macrophages in tumor microenvironment, and suggests a method to predict the effect of drugs in the presence of stromal cells to guide experimental designs in drug development. Keywords: TNF-α, Etanercept, Breast cancer, Macrophages, Systems biology Background hand, drug impacts are usually assayed in cell culture or Crosstalk between cancerous and stromal cells in an immunosuppressed mice models [5], neither of which inflammatory-based microenvironment not only affects provides a clear picture of the complicated interactions the aggressive behavior of cancer cell, but also influences between tumor cells and their surrounding inflammatory the efficacy of anti-cancer drugs [1–4]. On the other stroma, eventually resulting in inconsistencies in the outcome of clinical trials [6]. It is thus naïve to assess the sole effect of inhibiting a drugable target in the ag- * Correspondence: [email protected] 3Physiology and Pharmacology Department, Pasteur Institute of Iran, P.O. gressive cancer cells while ignoring the context of Box: 13164, Tehran, Iran micro-environmental changes [4]. Communication Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Shirmohammadi et al. BMC Cancer (2020) 20:836 Page 2 of 10 between cancer cells and their surrounding stroma is factors and cytokines) and displays ligands inducing through secretion by these cells of soluble factors includ- similar gene expression profiles. ing growth factors, chemokines and cytokines [7]. The Gene-set enrichment tests including gene ontology secreted factors reprogram the surrounding stroma with (GO) biological process, transcription factors and signal- the aim of neutralizing the impact of various intruders ing pathways were carried out using the corresponding disrupting the survival of the cancer cells [8, 9]. libraries embedded in Enrichr online web tool. One of the most influential cytokines in tumor micro- environment is Tumor Necrosis Factor-alpha (TNF-α) [10, 11], long known for its dual effects cancer [12]. De- Boolean network simulation pending on the cellular context as well as its concentra- Cellular signaling network was constructed based on the tion, the effects of TNF-α may vary from inducing literature survey [19] and translated into Boolean rules. necrosis to survival benefits, endowing invasive proper- Asynchronous simulation mode was used to predict the ties and driving epithelial-mesenchymal transition effect of macrophages on the anti-cancer efficacy of Eta- (EMT) [13]. nercept. BoolNet R package was used to perform the dy- Considering the pleiotropic and conflicting effects of namic modeling and analysis of attractor states [20]. TNF-α, various efforts have been made to exploit this cytokine as a therapeutic target in cancer. In this regard, Cell culture and condition medium preparation α some approaches have used TNF- administration to MDA-MB-231 human breast cancer cell line and THP-1 tumor tissue to induce cell death due to its necrotizing human monocytic cells were purchased from Pasteur In- α effects [14]. However, using TNF- as a necrotizing stitute of Iran (Tehran, Iran). A total of 2 × 105 THP-1 agent has been associated with significant lethal side ef- cells were seeded in 2 ml RPMI supplemented with 10% α fects limiting the applicability of TNF- administration FBS in the upper chamber of 6-well insert plates (SPL α to patients [15]. On the other side, TNF- activates Life Sciences, Seoul, South Korea). Cells were treated NFKB transcription factor along with JNK and p38 in a with 10 ng/ml of PMA (Phorbol 12-myristate 13-acetate) cellular context-dependent manner [16]. This canonical for 24 h to allow differentiation of THP-1 cells to M0 pathway induces the expression of several downstream macrophages and their subsequent attachment to the in- targets of NFKB leading to the increased invasiveness of serts. After 24 h, 2 × 105 of MDA-MB-231 cells were cancer cells. A different approach that has attracted a seeded in the lower chamber in 2 ml of DMEM. The co- α great of attention is the use of TNF- inhibitors, such as culturing system was kept in 5% CO2 incubator for 72 h. Etanercept, as candidates for cancer biotherapy [17]. To prepare condition medium (CM), the upper insert α Etanercept is a dimeric soluble receptor for TNF- , was withdrawn and MDA-MB-231 cells were washed 3 which competes with the cell surface receptors For TNF times with PBS and starved for 24 h in the serum free binding. A phase II clinical trial evaluating the thera- DMEM. The condition medium was then filtered using peutic efficacy of Etanercept in patients with advanced 0.2 μm filter and kept at − 70 °C until use. CM was di- metastatic breast cancer revealed a reduction in the con- luted with 50% of fresh medium for further experiments. centration of TNF-α related cytokines such as CCL2; however, disease stabilization was detected in only one patient [18]. In order to elucidate the underlying reason Tetrazolium-based viability test for this outcome, we aimed at integrating molecular- Co-culturing of MDA-MB-231 with THP-1 cells was cellular experiments with systems modeling approaches performed as described in the previous section. Co- to compare the effect of Etanercept in breast cancer cells cultured as well as MDA-MB-231 cells were treated with alone and in the context of host immune cells. 1or10μg/ml of Etanercept (Aryogen Pharmed, Tehran, Iran) or control buffer for 72 h. The concentration of Etanercept was selected based on the plasma concentra- Methods tion obtained after weekly administration of the drug to High through-put data analysis and enrichment-based the arthritis rheumatoid patients [7]. After 72 h, THP-1 tests containing inserts were discarded, and 20 μl of 5 mg/ml Proteomics data providing the secretome of MDA-MB- of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra- 231 cells were extracted from GSE51938 dataset in zolium bromide) stock solution was added to each well. GEO. The secretion profile was submitted to Enrichr on- Following 3 h of incubation, the supernatants were aspi- line web (http://amp.pharm.mssm.edu/Enrichr/). “LINCS rated, and 200 μl of dimethylsulfoxide (DMSO) were L1000 Ligand Perturbations up” library was used for en- used to dissolve purple formazan in each well. Absorb- richment analysis. This library consists of gene expres- ance was measured at 545 nm using microplate Reader sion changes induced by various ligands (e.g. growth (Stat Fax-2100, ST. Louis, USA). Shirmohammadi et al. BMC Cancer (2020) 20:836 Page 3 of 10 Cell cycle analysis Quantitative real time PCR for the analysis of macrophage MDA-MB-231 cells were harvested after 72 h of co- cytokines culturing with the differentiated macrophages in the A total of 1 × 106 of differentiated THP-1 cells using10 presence and absence of 1 or 10 μg/ml Etanercept.
Recommended publications
  • T Cell Binding to Activated Dendritic Cells Cutting Edge
    Cutting Edge: CCR4 Mediates Antigen-Primed T Cell Binding to Activated Dendritic Cells Meng-tse Wu, Hui Fang and Sam T. Hwang This information is current as J Immunol 2001; 167:4791-4795; ; of September 27, 2021. doi: 10.4049/jimmunol.167.9.4791 http://www.jimmunol.org/content/167/9/4791 Supplementary http://www.jimmunol.org/content/suppl/2001/10/11/167.9.4791.DC1 Downloaded from Material References This article cites 32 articles, 13 of which you can access for free at: http://www.jimmunol.org/content/167/9/4791.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. ● Cutting Edge: CCR4 Mediates Antigen-Primed T Cell Binding to Activated Dendritic Cells Meng-tse Wu, Hui Fang, and Sam T. Hwang1 DC. In the periphery, activated, Ag-bearing DC may bind to cog- The binding of a T cell to an Ag-laden dendritic cell (DC) is a nate effector memory T cells (mTC).
    [Show full text]
  • Mechanism of Macrophage-Derived Chemokine/CCL22 Production by Hacat Keratinocytes
    C Yano, et al Ann Dermatol Vol. 27, No. 2, 2015 http://dx.doi.org/10.5021/ad.2015.27.2.152 ORIGINAL ARTICLE Mechanism of Macrophage-Derived Chemokine/CCL22 Production by HaCaT Keratinocytes Chizuko Yano, Hidehisa Saeki1, Mayumi Komine2, Shinji Kagami3, Yuichiro Tsunemi4, Mamitaro Ohtsuki2, Hidemi Nakagawa Department of Dermatology, The Jikei University School of Medicine, 1Department of Dermatology, Nippon Medical School, Tokyo, 2Department of Dermatology, Jichi Medical University, Shimotsuke, 3Department of Dermatology, Kanto Central Hospital, 4Department of Dermatology, Tokyo Women’s Medical University, Tokyo, Japan Background: CC chemokine ligand 17 (CCL17) and CCL22 27(2) 152∼156, 2015) are the functional ligands for CCR4. We previously reported that inhibitors of nuclear factor-kappa B and p38 mi- -Keywords- togen-activated protein kinase (p38 MAPK), but not of ex- Chemokine CCL22, Chemokine CCL17, Epidermal growth tracellular signal-related kinase (ERK), inhibited tumor ne- factor receptor, HaCaT keratinocytes crosis factor (TNF)-α- and interferon (IFN)-γ-induced pro- duction of CCL17 by the human keratinocyte cell line, HaCaT. Further, an inhibitor of epidermal growth factor re- INTRODUCTION ceptor (EGFR) enhanced the CCL17 production by these keratinocytes. Objective: To identify the mechanism under- The macrophage-derived chemokine (MDC)/CC chemo- lying CCL22 production by HaCaT cells. Methods: We inves- kine ligand 22 (CCL22) is one of the functional ligands for tigated the signal transduction pathways by which TNF-α CC chemokine receptor 4 (CCR4) and is a chemoattractant and IFN-γ stimulate HaCaT cells to produce CCL22 by add- for the CCR4-expressing cells such as Th2 cells. We and ing various inhibitors.
    [Show full text]
  • Differential Expression of Interferon-Γ and Chemokine Genes
    Differential expression of interferon-γ and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response Owens et al. Owens et al. Journal of Neuroinflammation 2013, 10:56 http://www.jneuroinflammation.com/content/10/1/56 Owens et al. Journal of Neuroinflammation 2013, 10:56 JOURNAL OF http://www.jneuroinflammation.com/content/10/1/56 NEUROINFLAMMATION RESEARCH Open Access Differential expression of interferon-γ and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response Geoffrey C Owens1,7*, My N Huynh1, Julia W Chang1, David L McArthur1, Michelle J Hickey2, Harry V Vinters2,3, Gary W Mathern1,4,5,6† and Carol A Kruse1,6† Abstract Background: Rasmussen encephalitis (RE) is a rare complex inflammatory disease, primarily seen in young children, that is characterized by severe partial seizures and brain atrophy. Surgery is currently the only effective treatment option. To identify genes specifically associated with the immunopathology in RE, RNA transcripts of genes involved in inflammation and autoimmunity were measured in brain tissue from RE surgeries and compared with those in surgical specimens of cortical dysplasia (CD), a major cause of intractable pediatric epilepsy. Methods: Quantitative polymerase chain reactions measured the relative expression of 84 genes related to inflammation and autoimmunity in 12 RE specimens and in the reference group of 12 CD surgical specimens. Data were analyzed by consensus clustering using the entire dataset, and by pairwise comparison of gene expression levels between the RE and CD cohorts using the Harrell-Davis distribution-free quantile estimator method.
    [Show full text]
  • Plasma Macrophage-Derived Chemokine (CCL22) and Its
    Egypt J Pediatr Allergy Immunol 2005; 3(1): 20-31. Original article Plasma macrophage-derived chemokine (CCL22) and its receptor CCR4 on peripheral blood T lymphocytes of asthmatic children Background: The macrophage-derived chemokine (MDC/CCL22) acts on Mohamed H. Ezzat, CC chemokine receptor-4 (CCR4) to direct trafficking and recruitment of T Karim Y. Shaheen*. helper-2 (TH2) cells into sites of allergic inflammation. It was previously found overexpressed in lesional samples from adult asthmatics. Objective: This study is aimed to investigate the participation of CCR4/MDC axis in the development of TH2-dominated allergen-induced From the Departments childhood asthma in relation to disease activity, attack severity, and of Pediatrics and response to therapy, and to outline its value in differentiating atopic asthma Clinical Pathology*, from infection-associated airway reactivity. Faculty of Medicine, Methods: Proportion of CCR4-expressing peripheral blood T lymphocytes Ain Shams University, + (CCR4 PBTL%) were purified and quantitated by negative selection from Cairo, Egypt. peripheral blood mononuclear cells by flow cytometry, and the concentration of MDC in plasma was measured by ELISA in 32 children with atopic asthma (during exacerbation and remission), as well as in 12 children with acute lower respiratory tract infections (ALRTI), and 20 healthy children serving as controls. Results: The mean plasma MDC level (925±471.5 pg/ml) and CCR4+PBTL% (55.3±23.6%) were significantly higher in asthmatic children during acute attacks in comparison to children with ALRTI (109±27.3 pg/ml and 27.6±7.5%) and healthy controls (99.6±25.6 pg/ml and 24.2±4.1%).
    [Show full text]
  • Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration
    Published OnlineFirst October 2, 2015; DOI: 10.1158/0008-5472.CAN-14-3499 Cancer Microenvironment and Immunology Research Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression David Anz1,2, Moritz Rapp1, Stephan Eiber1,2, Viktor H. Koelzer1, Raffael Thaler1, Sascha Haubner1, Max Knott1, Sarah Nagel1, Michaela Golic1, Gabriela M. Wiedemann1, Franz Bauernfeind3, Cornelia Wurzenberger1, Veit Hornung3,4, Christoph Scholz5, Doris Mayr6, Simon Rothenfusser1, Stefan Endres1, and Carole Bourquin1,7 Abstract The chemokine CCL22 is abundantly expressed in many tion. Mechanistic investigations indicated that Treg blockade types of cancer and is instrumental for intratumoral recruit- was a consequence of reduced intratumoral CCL22 levels ment of regulatory T cells (Treg), an important subset of caused by type I IFN. Notably, stable expression of CCL22 immunosuppressive and tumor-promoting lymphocytes. In abrogated the antitumor effects of treatment with RLR or this study, we offer evidence for a generalized strategy to TLR ligands. Taken together, our findings argue that type I blunt Treg activity that can limit immune escape and promote IFN blocks the Treg-attracting chemokine CCL22 and thus tumor rejection. Activation of innate immunity with Toll-like helps limit the recruitment of Treg to tumors, a finding with receptor (TLR) or RIG-I–like receptor (RLR) ligands prevented implications for cancer immunotherapy. Cancer Res; 75(21); 1– accumulation of Treg in tumors by blocking their immigra- 11. Ó2015 AACR. Introduction effector T-cell function ex vivo (1). Indeed, suppression of anti- cancer immunity is mediated predominantly by intratumoral Treg The chemokine CCL22 is abundantly expressed in the tissue of that suppress CD8 T-cell responses locally at the tumor site (6).
    [Show full text]
  • HIV-1-Suppressive Factors Are Secreted by CD4 T Cells During
    HIV-1-suppressive factors are secreted by CD4؉ T cells during primary immune responses Sayed F. Abdelwahab*†, Fiorenza Cocchi*†, Kenneth C. Bagley*‡, Roberta Kamin-Lewis*†, Robert C. Gallo*†, Anthony DeVico*†, and George K. Lewis*†§ *Institute of Human Virology, University of Maryland Biotechnology Institute, and Departments of †Microbiology and Immunology and ‡Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201 Contributed by Robert C. Gallo, August 8, 2003 CD4؉ T cells are required for immunity against many viral infec- system faithfully mimics the early stages of the antigen-specific tions, including HIV-1 where a positive correlation has been ob- response of naı¨ve human CD4ϩ T cells, including clonal activa- served between strong recall responses and low HIV-1 viral loads. tion, expansion, contraction, and maintenance (unpublished Some HIV-1-specific CD4؉ T cells are preferentially infected with work and ref. 18). We used this system to study the kinetics of HIV-1, whereas others escape infection by unknown mechanisms. production of HIV-1-suppressive factors against both CXCR4 One possibility is that some CD4؉ T cells are protected from (X4) and CCR5 (R5) viruses. CD4ϩ T cells, starting as naı¨ve cells infection by the secretion of soluble HIV-suppressive factors, al- and differentiating in response to different antigens, secreted though it is not known whether these factors are produced during factors that inhibited both HIV-1IIIB (X4) and HIV-1BaL (R5). primary antigen-specific responses. Here, we show that soluble The anti-X4 factor is predominantly the CC chemokine CCL22 suppressive factors are produced against CXCR4 and CCR5 isolates (macrophage-derived chemokine), whereas the anti-R5 factors -of HIV-1 during the primary immune response of human CD4؉ T are CCL3 (macrophage inflammatory protein-1␣), CCL4 (mac cells.
    [Show full text]
  • Potential Inhibitory Effects of the Traditional Herbal Prescription
    MOLECULAR MEDICINE REPORTS 17: 2515-2522, 2018 Potential inhibitory effects of the traditional herbal prescription Hyangso‑san against skin inflammation via inhibition of chemokine production and inactivation of STAT1 in HaCaT keratinocytes HYE‑SUN LIM1, SAE‑ROM YOO2, MEE‑YOUNG LEE2, CHANG‑SEOB SEO2, HYEUN‑KYOO SHIN2 and SOO‑JIN JEONG1,3 1Herbal Medicine Research Division; 2K‑herb Research Center, Korea Institute of Oriental Medicine, Yuseong, Daejeon 34054; 3Korean Medicine Life Science, University of Science and Technology, Yuseong, Daejeon 34113, Republic of Korea Received June 15, 2016; Accepted April 20, 2017 DOI: 10.3892/mmr.2017.8172 Abstract. Inflammatory skin disease are caused by multiple treatment inhibited TNF‑α‑ and IFN‑γ‑induced STAT1 factors, including susceptibility genes, and immunologic and activation. Results from the present study indicated that HSS environmental factors, and are characterized by an increase exhibited inhibitory effects on TNF‑α‑ and IFN‑γ‑mediated in epidermal thickness and the infiltration of macrophages, chemokine production and expression by targeting STAT1 in keratinocytes, mast cells, eosinophils and other inflammatory keratinocytes. Overall, the results indicated that HSS may be cells. Keratinocytes may serve an important role in the patho- a potential candidate therapeutic drug for inflammatory skin genesis of inflammatory skin diseases. The traditional herbal diseases such as atopic dermatitis. decoction Hyangso‑san (HSS) has been used to treat symp- toms of the common cold, including headache, pantalgia, fever Introduction and chills. However, to the best of our knowledge, there is no evidence regarding whether HSS has an effect on inflamma- Skin inflammation is the most common complaint in derma- tory skin diseases.
    [Show full text]
  • Cord Blood Th2-Related Chemokine CCL22 Levels Associate with Elevated Total-Ige During Preschool Age
    Cord blood Th2-related chemokine CCL22 levels associate with elevated total-IgE during preschool age N V Folsgaard, B L K Chawes, K Bonnelykke, Maria Jenmalm and H Bisgaard Linköping University Post Print N.B.: When citing this work, cite the original article. This is the authors’ version of the following article: N V Folsgaard, B L K Chawes, K Bonnelykke, Maria Jenmalm and H Bisgaard, Cord blood Th2-related chemokine CCL22 levels associate with elevated total-IgE during preschool age, 2012, Clinical and Experimental Allergy, (42), 11, 1596-1603. which has been published in final form at: http://dx.doi.org/10.1111/j.1365-2222.2012.04048.x Copyright: Blackwell Publishing http://www.blackwellpublishing.com/ Postprint available at: Linköping University Electronic Press http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-85850 1 Cord Blood Th2-related Chemokine CCL22 Levels Associate with Elevated Total-IgE during Preschool Age Følsgaard NV, MD1, Chawes BL, MD, PhD 1, Bønnelykke K, MD, PhD 1, Jenmalm MC, PhD2, Bisgaard H, MD, DMsc1. 1. Copenhagen Prospective Studies on Asthma in Childhood; Copenhagen University Hospital, Gentofte, Denmark. 2. Department of Clinical and Experimental Medicine, Linköping University, Sweden Correspondence and request for reprints: Professor Hans Bisgaard Copenhagen Prospective Studies on Asthma in Childhood Copenhagen University Hospital; Gentofte Ledreborg Allé 34 DK-2820 Gentofte Copenhagen Denmark Tel: +45 39 77 7360 Fax: +45 39 77 7129 E-mail: [email protected] Website: www.copsac.com 2 Source of funding and conflict of interest: COPSAC is funded by private and public research funds all listed on www.copsac.com.
    [Show full text]
  • Expression and Regulation of Chemokines in Murine and Human Type 1 Diabetes Suparna A
    ORIGINAL ARTICLE Expression and Regulation of Chemokines in Murine and Human Type 1 Diabetes Suparna A. Sarkar,1 Catherine E. Lee,1 Francisco Victorino,1,2 Tom T. Nguyen,1 Jay A. Walters,1 Adam Burrack,1,2 Jens Eberlein,1 Steven K. Hildemann,3 and Dirk Homann1,2,4 fl – More than one-half of the ~50 human chemokines have been in ammation (1 3), and multiple chemokines and chemokine associated with or implicated in the pathogenesis of type 1 receptors have emerged as pertinent contributors to the diabetes, yet their actual expression patterns in the islet environ- natural history of various autoimmune disorders, including ment of type 1 diabetic patients remain, at present, poorly defined. type 1 diabetes; potential biomarkers; and possible drug Here, we have integrated a human islet culture system, murine targets (4–8). In fact, work conducted over the past 20 models of virus-induced and spontaneous type 1 diabetes, and the years has implicated more than one-half of all human and/ histopathological examination of pancreata from diabetic organ or rodent chemokines in the pathogenesis of type 1 diabetes donors with the goal of providing a foundation for the informed and/or its complications, although much of the work pub- selection of potential therapeutic targets within the chemokine/ receptor family. Chemokine (C-C motif) ligand (CCL) 5 (CCL5), lished to date on human type 1 diabetes and chemokines CCL8, CCL22, chemokine (C-X-C motif) ligand (CXCL) 9 (CXCL9), remains limited to genetic association studies and che- CXCL10, and chemokine (C-X3-C motif) ligand (CX3CL) 1 (CX3CL1) mokine/receptor analyses in peripheral blood (9–23).
    [Show full text]
  • Immunomodulatory Effect of Imiquimod Through CCL22
    ANTICANCER RESEARCH 37 : 3461-3471 (2017) doi:10.21873/anticanres.11714 Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas SADANORI FURUDATE*, TAKU FUJIMURA*, YUMI KAMBAYASHI, AYA KAKIZAKI, TAKANORI HIDAKA and SETSUYA AIBA Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan Abstract. Background/Aim: Tumor-associated macrophages the tumor site. Conclusion: Our results suggest a possible (TAMs), together with splenic CD11b + cells, help maintain the mechanism for the antitumor immune response induced by tumor microenvironment. The immunomodulatory compound IQM through tumor-associated macrophages. imiquimod (IQM) stimulates innate immune cells, including macrophages, to induce antitumor effects. In order to elucidate Imiquimod (IQM) is an immunomodulatory, small-molecule the effects of IQM on the tumor microenvironment, we compound in the imidazoquinoline family that induces antitumor investigated the immunomodulatory effect of IQM during effects through Toll-like receptor 7 (TLR7). As a TLR7 agonist, melanoma growth by using the B16F10 melanoma model. IQM stimulates innate immunity, including tumor-associated Materials and Methods: To elucidate the immunomodulatory macrophages (TAMs) (1-3). In an experimental murine model, effects of IQM on the tumor microenvironment, we isolated the addition of IQM to cryosurgery increased the cellular CD11b + TAMs and splenic CD11b + cells and evaluated the immune response against tumor antigens, leading to
    [Show full text]
  • E000764.Full.Pdf
    Open access Original research J Immunother Cancer: first published as 10.1136/jitc-2020-000764 on 26 November 2020. Downloaded from Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4 Lisa A Marshall,1 Sachie Marubayashi,2 Aparna Jorapur,1 Scott Jacobson,1 Mikhail Zibinsky,1 Omar Robles,1 Dennis Xiaozhou Hu,3 Jeffrey J Jackson,1 Deepa Pookot,1 Jerick Sanchez,1 Martin Brovarney,1 Angela Wadsworth,1 David Chian,4 David Wustrow,1 Paul D Kassner,1 Gene Cutler,1 Brian Wong,1 1 1 Dirk G Brockstedt, Oezcan Talay To cite: Marshall LA, ABSTRACT Statement of significance CPI upregulates CCL17 and Marubayashi S, Jorapur A, et al. Background Checkpoint inhibitors (CPIs) such as anti- CCL22 expression in tumors and increases Treg migration Tumors establish resistance to PD(L)-1 and anti- CTLA-4 antibodies have resulted in into the TME. Pharmacological antagonism of the CCR4 immunotherapy by regulating unprecedented rates of antitumor responses and extension receptor effectively inhibits T recruitment and results T recruitment via CCR4. reg reg of survival of patients with a variety of cancers. But in enhanced antitumor efficacy either as single agent in Journal for ImmunoTherapy some patients fail to respond or initially respond but later CCR4 ligandhigh tumors or in combination with CPIs in of Cancer 2020;8:e000764. low doi:10.1136/jitc-2020-000764 relapse as they develop resistance to immune therapy. CCR4 ligand tumors. One of the tumor- extrinsic mechanisms for resistance to immune therapy is the accumulation of regulatory T cells ► Additional material is published online only.
    [Show full text]
  • Innate Immune Recognition Trigger CCL22 by Breast Tumor Cells”
    Author Manuscript Published OnlineFirst on August 18, 2011; DOI: 10.1158/0008-5472.CAN-11-0573 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Faget et al “innate immune recognition trigger CCL22 by breast tumor cells” Early detection of tumor cells by innate immune cells leads to Treg recruitment through CCL22 production by tumor cells Running title : innate immune recognition trigger CCL22 by breast tumor cells Julien Faget1,2,3, Cathy Biota1,2,3, Thomas Bachelot1,2,3, Michael Gobert1,2,3, Isabelle Treilleux1,2,3, Nadège Goutagny1,2,3, Isabelle Durand1,3, Sophie Léon-Goddard1,2,3, Jean Yves Blay1,2,3, Christophe Caux1,2,3 and Christine Ménétrier-Caux1,2,3 Affiliations : 1- Centre Léon Bérard, Lyon, France, 2- Université Lyon 1, F-69000 Lyon, France, 3- Inserm U1052, Centre de Recherche en Cancérologie de Lyon, F-69000 Lyon, France Corresponding author: Dr Christine MENETRIER-CAUX, Centre Léon Bérard, CRCL INSERM U1052/CNRS 5286, 28 rue Laennec, 69373 Lyon cedex 08, France; Tel : (33) 4 78 78 27 50; Fax : (33) 4 78 78 27 20; e-mail : [email protected] Key-words : CCL22, Treg, tumor cells, breast carcinoma, recruitment Scientific category: Immunology Conflict of interest disclosure: The authors declare no competing financial interest. Aknowledgments : JF and MG are grant holders of the Ligue Nationale contre le Cancer. This work was financially supported in part by grants from “le comité départemental du Rhône de Ligue Contre le Cancer “,the ARC association (ARC-5074), the Breast Cancer Research Fundation and Institut National du Cancer grant INCA ACI-63-04, ACI 2007-2009.
    [Show full text]